Premium
Three‐dimensional MR imaging of pulmonary vessels and parenchyma with NC100150 injection (Clariscan™)
Author(s) -
Bremerich Jens,
Roberts Timothy P.L.,
Wendland Michael F.,
Wyttenbach Rolf,
Arheden Håkan,
Reddy Gautham P.,
Shafaghi Neda,
Higgins Charles B.,
Saeed Maythem
Publication year - 2000
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/1522-2586(200006)11:6<622::aid-jmri8>3.0.co;2-0
Subject(s) - parenchyma , medicine , magnetic resonance imaging , nuclear medicine , radiology , pathology
The influence of increasing doses of NC100150 Injection (Clariscan™) and echo times on visualization of pulmonary vessels and parenchyma was evaluated. The effects of 0.5, 1, 2, 4, and 8 mg Fe/kg NC100150 Injection and echo times (TE) of 1.1, 1.8, 2.2, and 4.3 msec were determined in six dogs using breath‐hold three‐dimensional (3D) spoiled gradient‐echo magnetic resonance (MR) sequence. At 2 mg Fe/kg and TE of 1.1 msec, the signal‐to‐noise ratio of the central pulmonary arteries and parenchyma was significantly increased (5.3 ± 2.2 to 50.3 ± 2.4) and (2.2 ± 0.9 to 6.4 ± 1.1), respectively. Using the TE of 1.1 msec, signal intensity in the main arteries continued to increase with increasing dose. Moreover, the enhancement of pulmonary parenchyma and microvasculature had a positive dose response. 3D MR imaging with ultrashort echo time and 2 mg Fe/kg NC100150 Injection produces angiograms with strong vascular contrast and allows qualitative assessment of pulmonary parenchyma and microvasculature. J. Magn. Reson. Imaging 2000;11:622–628. © 2000 Wiley‐Liss, Inc.